| Literature DB >> 35403331 |
Souvik Dubey1, Subhankar Chatterjee2, Ritwik Ghosh3, Elan D Louis4, Avijit Hazra5, Samya Sengupta6, Shambaditya Das1, Abhirup Banerjee7, Alak Pandit1, Biman Kanti Ray1, Julián Benito-León8,9,10.
Abstract
BACKGROUND ANDEntities:
Keywords: Choreoballism; Diabetes mellitus; Diabetic striatopathy; Hyperglycemia; Movement disorders
Mesh:
Year: 2022 PMID: 35403331 PMCID: PMC9542887 DOI: 10.1111/ene.15353
Source DB: PubMed Journal: Eur J Neurol ISSN: 1351-5101 Impact factor: 6.288
Previous selected clinical series and systematic reviews of acute onset movement disorders in diabetes mellitus
| Authors | Study type | Sample size | Type of movement disorder | Ketosis/nonketosis | Mean age, years | Men:women | Mean blood glucose, mg/dl | Mean glycated hemoglobin, % | Anatomical area involved | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Chua et al. [ | Systematic review | 176 | Chorea–ballism | Both | 67.6 | 1:1.7 | 414 | 13.1 | Putamen | Successful treatment with glucose control only and neuroleptics. The recurrence rate was 18.2%. There were discrepancies in clinical–radiological manifestations. |
| Ryan et al. [ | Retrospective study | 7 | Chorea–ballism | Not mentioned | 80 | 1:2.5 | Not mentioned | Not mentioned | Putamen | Only one patient had resolution after hyperglycemia correction; all others received neuroleptics. |
| Gómez‐Ochoa et al. [ | Meta‐analysis | 286 | Chorea–ballism | Both | 72 (median) | 1:1.7 | 420 (median) | 14 (median) | Putamen | 84.9% reported having complete clinical recovery. Neuroleptics were prescribed to 60.8% of the patients. |
| Cosentino et al. [ | Case series | 20 | Chorea–ballism | Nonketosis | 67.8 | 1:1.3 | 306.7 | Not mentioned | Putamen | All patients recovered. Neuroleptics were prescribed to all patients. |
| Guo et al. [ | Retrospective study | 12 | Hemichorea | Nonketosis | 74.9 | 1:3 | 330.7 | 11.4 | Putamen | Complete clinical resolution in all patients; 41.7% had recurrences; 66.7% needed neuroleptics. |
| Chen et al. [ | Systematic review | 15 | Chorea–ballism | Ketosis | 54.1 | 1:2.8 | 654.4 | Not mentioned | Putamen | Complete clinical resolution in 93.3% of the patients; 40% needed neuroleptics. |
| Prabhu and Ramya [ | Retrospective study | 11 | Chorea–ballism–athetosis | Not mentioned | 58.7 | 1:1.8 | 329.4 | 11.7 | Putamen/caudate | 100% clinical recovery. 45.5% received neuroleptics. |
| Lee et al. [ | Retrospective study | 25 | Chorea–ballism | Both | 73.5 | 1:1.8 | 451.6 | 13.5 | Not mentioned | A complete clinical resolution was observed in 92%. 76% required neuroleptics. |
| Oh et al. [ | Meta‐analysis | 53 | Chorea | ‐ | 71.1 | 1:1.8 | 481.5 | 14.4 | Putamen | 73.6% had complete clinical resolution. 13.2% had a recurrence. |
| Lee et al. [ | Case series | 8 | Chorea–ballism | ‐ | 70 | All were women | 323.5 | 12.9 | Putamen | All had complete clinical recovery. 75% received neuroleptics. |
FIGURE 1Flowchart showing stratification of total patients attended with acute onset movement disorders in this study. ADA, American Diabetes Association [17]; EPC, epilepsia partialis continua [Colour figure can be viewed at wileyonlinelibrary.com]
Demographics and diabetes mellitus‐related data (N = 59)
| Characteristic | Value |
|---|---|
| Age, years, mean ± SD | 55.4 ± 14.3 |
| Sex, | |
|
| 31 (52.5%) |
|
| 28 (47.5%) |
| Diabetes mellitus type, | |
|
| 6 (10.2%) |
|
| 53 (89.8%) |
| Diabetes mellitus duration, years, mean ± SD | 9.8 ± 11.4 |
| Capillary blood glucose upon admission, mg/dl, mean ± SD | 419.6 ± 89.3 |
| Glycated hemoglobin, %, mean ± SD | 10.5% ± 1.8% |
| Time from onset of movement disorders to clinical assessment, days | 10.8 ± 32.9 |
| Chronic diabetic complications, | |
| Nephropathy | |
|
| 49 (83.1%) |
|
| 10 (16.9%) |
| Neuropathy | |
|
| 30 (50.8%) |
|
| 29 (49.2%) |
| Retinopathy | |
|
| 35 (59.3%) |
|
| 24 (40.7%) |
| Acute hyperglycemic complications, | |
|
| 14 (23.7%) |
|
| 45 (76.3%) |
Clinical and neuroradiological characteristics of acute movement disorders among diabetic patients (N = 59)
| Characteristic |
|
|---|---|
| Type of movement disorder | |
| Choreic and ballistic | 41 (69.5% of the total) |
|
| 18 (30.5%) |
|
| 15 (25.4%) |
|
| 8 (13.6%) |
| Nonchoreic and nonballistic | 18 (30.5% of the total) |
|
| 5 (8.5%) |
|
| 3 (5.1%) |
|
| 3 (5.1%) |
|
| 3 (5.1%) |
|
| 2 (3.4%) |
|
| 2 (3.4%) |
| Sidedness of involuntary movement | |
|
| 37 (62.7%) |
|
| 22 (37.3%) |
| Brain magnetic resonance imaging changes | |
|
| 26 (44.1% of the total) |
| Concordant with clinical presentations | 18 (69.2%) |
| Discordant with clinical presentations | 8 (30.8%) |
|
| 33 (55.9% of the total) |
| Drug(s) given other than insulin | |
|
| 32 (54.2%) |
|
| 27 (45.8%) |
| Clinical outcome | |
|
| 28 (47.5%) |
|
| 17 (28.8%) |
|
| 14 (23.7%) |
Diabetes mellitus‐ and movement disorders‐related characteristics of the patients upon admission: comparisons of choreic and ballistic movements group versus nonchoreic and nonballistic movements group
| Characteristic | Choreic and ballistic movements group, | Nonchoreic and nonballistic movements group, |
|
|---|---|---|---|
| Age, years | 57.6 (60.0) ± 11.7 | 50.2 (52.5) ± 18.4 | 0.229 |
| Sex, men | 22 (53.7%) | 9 (50.0%) | 0.796 |
| Duration of diabetes mellitus, years | 10.8 (8.0) ± 13.3 | 7.6 (7.0) ± 4.7 | 0.547 |
| Diabetes mellitus type 2 | 39 (95.1%) | 14 (77.8%) | 0.064 |
| Chronic hyperglycemic complications | |||
|
| 26 (63.4%) | 9 (50.0%) | 0.334 |
|
| 22 (53.7%) | 8 (44.4%) | 0.514 |
|
| 34 (82.9%) | 14 (77.8%) | 0.721 |
| Time from onset of movement disorders to clinical assessment, days | 5.0 (2.0) ± 11.0 | 24.1 (6.0) ± 56.1 | 0.03 |
| Acute hyperglycemic complications | |||
|
| 10 (24.4%) | 4 (22.2%) | 1.0 |
|
| 31 (75.6%) | 14 (77.8%) | |
| Sidedness of movement | |||
|
| 33 (80.5%) | 4 (22.2%) | 0.001 |
|
| 8 (19.5%) | 14 (77.8%) | |
| Drug(s) given other than insulin | 22 (53.7%) | 10 (55.6%) | 0.893 |
| Clinical outcome | |||
|
| 18 (43.9%) | 10 (55.6%) | 0.679 |
|
| 13 (31.7%) | 4 (22.2%) | |
|
| 10 (24.4%) | 4 (22.2%) | |
| Glycated hemoglobin, % | 10.4 (10.3) ± 1.6 | 10.8 (10.0) ± 2.3 | 0.889 |
| Capillary blood glucose, mg/dl | 413.6 (402.0) ± 85.0 | 433.4 (442.5) ± 99.1 | 0.553 |
Mean (median) ± SD and frequency (%) are reported. All significant differences have been corrected for familywise error rate with the Benjamini–Hochberg procedure, with a defined false discovery (FDR) rate of 5%.
Mann–Whitney U test.
Chi‐squared test or Fisher exact test, when appropriate.
FDR‐adjusted p < 0.05.